This content is from: Innovation
KKR To Buy Capsugel For $2.38B
Private-equity firm, Kohlberg Kravis Roberts & Company, will acquire Pfizer’s unit Capsugel.
Private-equity firm, Kohlberg Kravis Roberts & Company, will acquire Pfizer’s unit Capsugel, The Wall Street Journal reports. The maker of hard capsules and other drug-delivery systems will be sold for about $2.38 billion in cash.
The deal is expected to be completed by the third quarter of 2011. Simpson Thacher & Bartlett was appointed as the legal counsel for KKR, while Morgan Stanley and Guggenheim Securities were financial advisers for the drug maker, adds Bloomberg.
Click here for the story from The Wall Street Journal.
Click here for the additional coverage from Bloomberg.